The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes
Open accessAbstract
BACKGROUND: Metformin reduces plasma glucose and has been shown to increase glucagon-like peptide 1 (GLP-1) secretion. Whether this is a direct action of metformin on GLP-1 release, and whether some of the glucose-lowering effect of metformin occurs due to GLP-1 release, is unknown. The current study investigated metformin-induced GLP-1 secretion and its contribution to the overall glucose-lowering effect of metformin and underlying mechanisms in patients with type 2 diabetes. METHODS: Twelve patients with type 2 diabetes were included in this placebo-controlled, double-blinded study. On 4 separate days, the patients received metformin (1,500 mg) or placebo suspended in a liquid meal, with subsequent i.v. infusion of the GLP-1 receptor antagonist exendin9-39 (Ex9-39) or saline. During 240 minutes, blood was sampled. The direct effect of metformin on GLP-1 secretion was tested ex vivo in human ileal and colonic tissue with and without dorsomorphin-induced inhibiting of the AMPK activity. RESULTS: Metformin increased postprandial GLP-1 secretion compared with placebo (P = 0.014), and the postprandial glucose excursions were significantly smaller after metformin + saline compared with metformin + Ex9-39 (P = 0.004). Ex vivo metformin acutely increased GLP-1 secretion (colonic tissue, P < 0.01; ileal tissue, P < 0.05), but the effect was abolished by inhibition of AMPK activity. CONCLUSIONS: Metformin has a direct and AMPK-dependent effect on GLP-1-secreting L cells and increases postprandial GLP-1 secretion, which seems to contribute to metformin's glucose-lowering effect and mode of action. TRIAL REGISTRATION: NCT02050074 (https://clinicaltrials.gov/ct2/show/NCT02050074). FUNDING: This study received grants from the A.P. Møller Foundation, the Novo Nordisk Foundation, the Danish Medical Association research grant, the Australian Research Council, the National Health and Medical Research Council, and Pfizer Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, and also via gut-mediated action, metformin enhances the release of glucagon-like peptide-1 (GLP-1).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [91]
In the citing paper
“It is the release of GLP-1 that contributes substantially to the antihyperglycemic effects of metformin (26, 90, 91).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,393
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Identification of membrane-type receptor for bile acids (M-BAR)
Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., & Tanaka, K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02550-0 · Cited by 993
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Shu, Y., Sheardown, S. A., Brown, C., Owen, R., Zhang, S., Castro, R. A., Ianculescu, A. G., Lin, Y., Lo, J. C.-M., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 980
Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 887
Farnesoid X receptor is essential for normal glucose homeostasis
Ma, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25604 · Cited by 883
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Miller, R., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 845
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Metformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733
Cauter, E. V., Mestrez, F., Sturis, J., et al. (1992) · Diabetes · doi:10.2337/diabetes.41.3.368 · Cited by 643
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Schvarcz, E., Palmer, M., Aman, J., Horowitz, M., Stridsberg, M., & Berne, C. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70080-5 · Cited by 416
Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
DEFRONZO, R. A., BARZILAI, N., & SIMONSON, D. C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1294 · Cited by 408
Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Self-citationToft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339
Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325
Accurate measurement of cholecystokinin in plasma
Rehfeld, J. F. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.5.991 · Cited by 316
Activation of p38 MAP kinase enhances sensitivity of muscle glucose transport to insulin
Geiger, P. C., Wright, D. C., Han, D., & Holloszy, J. O. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00477.2004 · Cited by 306
Maida, A., Lamont, B. J., Cao, X., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1937-z · Cited by 300
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S. L., Nicholls, A. W., Baker, D., Horn, S. V., Thomas, E., Rajpal, D. K., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 293
Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276
Self-citationExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin
Fisher, J. S., Gao, J., Han, D.-H., Holloszy, J. O., & Nolte, L. A. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2002.282.1.e18 · Cited by 244
Deane, A. M., Nguyen, N. Q., Stevens, J. E., Fraser, R. J., Holloway, R. H., Besanko, L. K., Burgstad, C. M., Jones, K. L., Chapman, M. J., Rayner, C. K., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1503 · Cited by 240
Migoya, E. M., Bergeron, R., Miller, J., Snyder, R., Tanen, M., Hilliard, D., Weiss, B., Larson, P., Gutierrez, M., Jiang, G., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.184 · Cited by 177
Evidence of Extrapancreatic Glucagon Secretion in Man
Lund, A., Bagger, J. I., Albrechtsen, N. J. W., Christensen, M., Grøndahl, M. F. G., Hartmann, B., Mathiesen, E. R., Hansen, C. P., Storkholm, J. H., van Hall, G., et al. (2015) · Diabetes · doi:10.2337/db15-1541 · Cited by 167
Mulherin, A. J., Oh, A., Kim, H., Grieco, A. J., Lauffer, L. M., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1485 · Cited by 158
Keating, D. J., & Spencer, N. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.020 · Cited by 154
Mechanisms controlling glucose-induced GLP-1 secretion in human small intestine
Sun, E. W., de Fontgalland, D., Rabbitt, P., Hollington, P., Sposato, L., Due, S. L., Wattchow, D. A., Rayner, C. K., Deane, A. M., Young, R. L., et al. (2017) · Diabetes · doi:10.2337/db17-0058 · Cited by 152
Self-citationDeacon, C. F., Wamberg, S., Bie, P., Hughes, T., & Holst, J. J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 146
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response
Becker, M. L., Visser, L. E., van Schaik, R. H. N., Albert Hofman, D., Uitterlinden, A. G., & Stricker, B. H. C. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328333bb11 · Cited by 139
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
DeFronzo, R. A., Buse, J. B., Kim, T., Burns, C. M., Skare, S., Baron, A., & Fineman, M. S. (2016) · Diabetologia · doi:10.1007/s00125-016-3992-6 · Cited by 135
Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men
Geary, N., Kissileff, H. R., Pi-Sunyer, X., & Hinton, V. J. (1992) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1992.262.6.r975 · Cited by 134
Schwartz, S. L., Fonseca, V. A., Berner, B., Cramer, M., Chiang, Y.-K., & Lewin, A. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1967 · Cited by 132
Mather, H. M., Chaturvedi, N., & Kehely, A. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199808)15:8 · Cited by 129
Mannucci, E., Tesi, F., Bardini, G., Ognibene, A., Mg, P., Ciani, S., Pezzatini, A., Brogi, M., Dicembrini, I., Cremasco, F., et al. (2004) · PubMed · Cited by 128
Wu, T., Bound, M. J., Standfield, S., Gedulin, B. R., Jones, K. L., Horowitz, M., & Rayner, C. K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12043 · Cited by 124
The role of gut hormone peptide YY in energy and glucose homeostasis: Twelve years on
Manning, S., & Batterham, R. L. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170404 · Cited by 124
Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon.
Adrian, T. E., Ballantyne, G. H., Longo, W. E., Bilchik, A. J., Graham, S. E., Basson, M. D., Tierney, R. P., & Modlin, I. M. (1993) · Gut · doi:10.1136/gut.34.9.1219 · Cited by 115
Krarup, T., & Holst, J. J. (1984) · Regulatory Peptides · doi:10.1016/0167-0115(84)90005-3 · Cited by 109
The Effect of Intravenous Metformin on Glucose Metabolism During Hyperglycaemia in Type 2 Diabetes
Sum, C. ‐., Webster, J. M., Johnson, A. B., Catalano, C., Cooper, B. G., & Taylor, R. (1992) · Diabetic Medicine · doi:10.1111/j.1464-5491.1992.tb01716.x · Cited by 103
Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus
Hare, K. J., Knop, F. K., Asmar, M., Madsbad, S., Deacon, C. F., Holst, J. J., & Vilsbøll, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0921 · Cited by 103
Medhus, A. W., Lofthus, C. M., Bredesen, J. E., & Husebye, E. (2001) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2001.00249.x · Cited by 99
Hansen, M., Scheltema, M. J. V., Sonne, D. P., Hansen, J. S., Sperling, M., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12648 · Cited by 95
Vardarli, I., Arndt, E., Deacon, C. F., Holst, J. J., & Nauck, M. A. (2013) · Diabetes · doi:10.2337/db13-0805 · Cited by 92
Mechanisms of metformin action on glucose transport and metabolism in human adipocytes
Grisouard, J., Timper, K., Radimerski, T., Frey, D. M., Peterli, R., Kola, B., Korbonits, M., Herrmann, P. C., Krähenbühl, S., Zulewski, H., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.021 · Cited by 82
Raghupathi, R., Duffield, M. D., Zelkas, L., Meedeniya, A. C. B., Brookes, S. J., Sia, T. C., Wattchow, D. A., Spencer, N. J., & Keating, D. J. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.259796 · Cited by 79
Nicolaus, M., Brödl, J., Linke, R., Woerle, H., Göke, B., & Schirra, J. R. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0841 · Cited by 73
Involvement of glucagon‐like peptide‐1 in the glucose‐lowering effect of metformin
Bahne, E., Hansen, M., Brønden, A., Sonne, D. P., Vilsbøll, T., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12697 · Cited by 73
Wu, T., Thazhath, S. S., Bound, M. J., Jones, K. L., Horowitz, M., & Rayner, C. K. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.08.004 · Cited by 70
Sonne, D. P., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0309 · Cited by 65
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
Keller, J., Trautmann, M. E., Haber, H., Tham, L. S., Hunt, T., Mace, K., & Linnebjerg, H. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.08.005 · Cited by 61
Dujić, T., Zhou, K., Tavendale, R., Palmer, C. N. A., & Pearson, E. R. (2016) · Diabetes Care · doi:10.2337/dc16-0706 · Cited by 56
Effect of Glucagon-like Peptide-1 Receptor Antagonism on Appetite and Food Intake in Healthy Men
Steinert, R. E., Schirra, J., Meyer-Gerspach, A. C., Kienle, P., Fischer, H., Schulte, F., Goeke, B., & Beglinger, C. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.083246 · Cited by 52
Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells
Krizhanovskii, C., Patrone, C., Holst, J. J., Zhang, Q., & Sjöholm, Å. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0637-5 · Cited by 51
Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography.
Miceli, J. N., Aravind, M. K., Cohen, S. N., & Done, A. K. (1979) · Clinical Chemistry · doi:10.1093/clinchem/25.6.1002 · Cited by 50
Thondam, S. K., Cross, A., Cuthbertson, D. J., Wilding, J. P. H., & Daousi, C. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03675.x · Cited by 43
Tsilchorozidou, T., Batterham, R. L., & Conway, G. S. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03285.x · Cited by 34
The antidiabetic gutsy role of metformin uncovered?
Burcelin, R. (2013) · Gut · doi:10.1136/gutjnl-2013-305370 · Cited by 26
Gielkens, H. A. J. (1998) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655298750026787 · Cited by 21
Evolving Metformin Treatment Strategies in Type-2 Diabetes
Chacra, A. R. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f1bb · Cited by 20
Marzio, L., Falcucci, M., Ciccaglione, A. F., Malatesta, M. G., Lapenna, D., Ballone, E., Antonelli, C., & Grossi, L. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02208580 · Cited by 19
GLP-1—A Candidate Humoral Mediator for Glucose Control After Roux-en-Y Gastric Bypass
Schirra, J. R. J., & Göke, B. (2014) · Diabetes · doi:10.2337/db13-1660 · Cited by 13
Research works printed but not linked: 1
- Jorsal, 2014, Altered enteroendocrine expression of glucagon and somatostatin in the gut of patients with type 2 diabetes compared with healthy matched controls, Diabetologia, 57
Cited by
Sorted by citations
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
GDF15 mediates the effects of metformin on body weight and energy balance
Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584
The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release
Martin, A. M., Sun, E. W. L., Rogers, G. B., & Keating, D. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00428 · Cited by 402
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models
Allen, B. M., Hiam-Galvez, K. J., Burnett, C. E., Venida, A. C., DeBarge, R., Tenvooren, I., Marquez, D. M., Cho, N. W., Carmi, Y., & Spitzer, M. H. (2020) · Nature Medicine · doi:10.1038/s41591-020-0892-6 · Cited by 320
Metadata
- Authors
- Bahne, E., Sun, E. W. L., Young, R. L., Hansen, M., Sonne, D. P., Hansen, J. S., Rohde, U., Liou, A. P., Jackson, M. L., de Fontgalland, D., Rabbitt, P., Hollington, P., Sposato, L., Due, S., Wattchow, D. A., Rehfeld, J. F., Holst, J. J., Keating, D. J., Vilsbøll, T., & Knop, F. K.
- Affiliations
- Gentofte Hospital (DK)
- Flinders University (AU)
- South Australian Health and Medical Research Institute (AU)
- University of Copenhagen (DK)
- Pfizer (United States) (US)
- Discipline of Surgery, Flinders University, Adelaide, South Australia, Australia.
- Corresponding author
- Keating, Damien J.
- Knop, Filip K.
- ORCID
- Venue
- JCI Insight
- Published
- 2018-12-06
- Volume
- 3
- Issue
- 23
- ISSN
- 2379-3708 (ISSN-L)
- PMC
- PMC6328020
- OpenAlex
- W2903143648
- Cited by
- 173
- References
- 72
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 28 · 2023: 23 · 2022: 18 · 2021: 30 · 2020: 22 · 2019: 15
- FWCI
- 13.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- JCI Insight (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- AP Møller Fonden
- the Novo Nordisk Foundation
- Danish Medical Association
- Australian Research Council (LP150100419)
- National Health and Medical Research Council (APP1088737, APP1081182)
- Pfizer (Emerging science grant)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- metformin, glucagon-like peptide-1, GLP-1 secretion, type 2 diabetes, AMPK, exendin-9-39, GLP-1 receptor antagonists, postprandial blood glucose, L cells, glucose-lowering mechanism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Australia, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Metformin, Middle Aged, Postprandial Period, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
